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Abstract
Background: Deep brain stimulation of the subthalamic nucleus significantly improves motor
function in patients with severe Parkinson's disease. However, the effects on nonmotor aspects
remain uncertain. The present study investigated the effects of subthalamic nucleus deep brain
stimulation on mood and psychosocial functions in 33 patients with advanced Parkinson's disease
in a three year follow-up.
Methods: Self-rating questionnaires were administered to 33 patients prior to surgery as well as
three, six, twelve and 36 months after surgery.
Results:  In the long run, motor function significantly improved after surgery. Mood and
psychosocial functions transiently improved at one year but returned to baseline at 36 months after
surgery. In addition, we performed cluster and discriminant function analyses and revealed four
distinct psychosocial profiles, which remained relatively stable in the course of time. Two profiles
featured impaired psychosocial functioning while the other two of them were characterized by
greater psychosocial stability.
Conclusion: Compared to baseline no worsening in mood and psychosocial functions was found
three years after electrode implantation. Moreover, patients can be assigned to four distinct
psychosocial profiles that are relatively stable in the time course. Since these subtypes already exist
preoperatively the extent of psychosocial support can be anticipatory adjusted to the patients'
needs in order to enhance coping strategies and compliance. This would allow early detection and
even prevention of potential psychiatric adverse events after surgery. Given adequate psychosocial
support, these findings imply that patients with mild psychiatric disturbances should not be
excluded from surgery.
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Background
Parkinson's disease (PD) is a progressive movement disor-
der ensuing from dopaminergic depletion of the basal
ganglia, substantia nigra pars compacta. The resulting dis-
ruption of the motor circuit that connects the basal gan-
glia to the motor cortex leads to the clinical
manifestations of tremor, rigidity, bradykinesia and pos-
tural instability. Since limbic and associative loops are
also affected by dopaminergic loss, cognitive and behav-
ioural abnormalities are frequently encountered in PD
patients [1-4].
Deep brain stimulation (DBS) of the subthalamic nucleus
(STN) is an effective treatment to improve motor function
in patients with advanced Parkinson's disease. Studies
with respect to short- and long-term efficacy of STN-DBS
have shown marked improvements in motor function as
well as a reduction of antiparkinsonian drug treatment [5-
7].
However, the effects of STN DBS on psychosocial func-
tions are not well understood. Some studies reported pos-
itive changes in mood, depression and anxiety after
surgery [8-10].
Several investigations showed adverse effects of STN DBS
on mood. Although many of them were single case
reports, documented mood changes include depression
[11-13](hypo)mania [14-17],visual hallucinations [18] and
behavioural changes, like apathy, irritability, emotional
lability, hypersexuality and  aggressiveness  [5,12,17,19].
Some behavioural abnormalities were related to electrode
displacement [15,20,21] or to stimulation parameters
[18,22-24]. Changes may also be related to activity modi-
fication within the basal ganglia-thalamo-cortical circuits
by chronic stimulation of the STN.
Since there are hardly any long-term studies, the effects of
STN DBS on mood are incompletely understood. The aim
of the current study was to investigate both short- and
long-term effects of STN-DBS on mood and psychosocial
functions in a consecutive series of 33 patients with idio-
pathic PD. We analyzed patient data of the short-term fol-
low-up that have been gathered in the study of Kalteis et
al (2006) and additionally collected long-term data of the
same patients [25].
Methods
Patients
Patients were selected for STN DBS according to the CAP-
SIT-PD protocol [26]. Subjects had to meet following
inclusion criteria: diagnosis of idiopathic PD determined
by the presence of at least two of the four cardinal motor
symptoms; intractable motor fluctuations, disabling dys-
kinesias or freezing episodes; clear responsiveness to
dopaminergic substitution therapy, demonstrated by an
apomorphine test before surgery [27]; inconspicuous
brain magnetic resonance imaging (MRI) scan. Exclusion
criteria were previous neurosurgical history, native lan-
guage other than German, substance abuse, a mini-mental
state examination score (MMSE) below 24, presence of a
severe psychiatric disease based on the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) and
withheld informed consent.
35 consecutive patients obtained bilateral STN DBS dur-
ing the assessment period. Two subjects generally refused
to participate in the study. Hence, in the present investiga-
tion data of 33 PD patients (22 men, 11 women) were
evaluated at baseline (see Table 1). One year after surgery
patient number declined to 31 due to two deaths that
were unrelated to STN DBS. During the long-term follow-
up two patients withdrew informed consent, one patient
died and one patient was excluded due to severe cognitive
deterioration. In summary 27 subjects completed the
entire investigation.
The present study was approved by the Ethics-Committee
of the Medical University of Vienna (trial registration
number: 353/96).
Surgical procedure
35 patients were treated with bilateral implantation sur-
gery in a single operative session (Lead 3389, Medtronic
Inc.). Due to a lack of cooperation one patient received
the brain electrodes in two procedures. Implantation of
pulse generators was performed in a second procedure
one week later. We used the same surgical procedure
which was described elsewhere (25).
Assessments
To investigate short- and long-term effects of STN DBS all
patients administered clinical and self-rating question-
naires prior to surgery and four times postoperatively
(three, six, twelve and 36 months). To establish a baseline
score, patients were assessed three times prior to electrode
implantation, in fact eight to six weeks, four weeks and
two weeks.
Table 1: Patients characteristics at baseline: mean ± SD
Patients (n = 33) m (SD) range
Age (years) 60,15 (7,88) 38 – 72
Sex (men/women) 22/11 -
Education (years) 11,09 (2,61) 8 – 17
Profession (employed/pension/household) 3/27/3 -
Disease duration (years) 13,52 (4,82) 7 – 25
Hoehn and Yahr stage 3,76 (0,56) 3 – 5
Mini Mental State Examination (MMSE) 27,85 (1,37) 25 – 30BMC Neurology 2008, 8:43 http://www.biomedcentral.com/1471-2377/8/43
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Before surgery motor symptoms were evaluated on and
off medication, however psychological assessments were
exclusively conducted in the on state. After surgery
patients were assessed while receiving medication with
stimulators turned on.
Psychological assessment
Prior to surgery all patients underwent a comprehensive
psychological evaluation. The psychological assessment
included well-established self-rating scales commonly
used in the assessment of mood, psychological symptoms
and distress. All scales used were valid and reliable as well
as recommended to evaluate treatment effects.
Profile of Mood Scale (POMS)
This modified version consists of 35 adjectives clustered
in four subscales (Depression, Fatigue, Vigor, Irritability)
by which subjects describe their mood during the week
before [28].
Visual Analogue Scale for Well-being (VAS)
The patient has to state his present condition on a line
with two extreme poles of well-being and discomfort [29].
Beck Depression Inventory (BDI)
The BDI is a commonly used 21-item questionnaire meas-
uring depressive symptoms [30].
State-Trait Anxiety Inventory (STAI-X1/STAI-X2)
The STAI consists of two rating scales: STAI-X1 evaluates
anxiety related to certain situations whereas STAI-X2
measures anxiety as a trait [31].
Self-Report Symptom Inventory 90 Items-Revised (SCL-90-R)
The SCL-90-R measures impairments due to somatic and
psychological symptoms and distress. It comprises nine
subscales and three global judgements [32].
Sickness Impact Profile (SIP)
The SIP is a 136-item generic quality of life instrument
and consists of 12 categories that can be divided into a
physical and a psychosocial domain of quality of life [33].
Unified Parkinson's Disease Rating Scale (UPDRS)
The severity of motor symptoms is assessed with the
UPRDS-Scale [34]. Part II (activities of daily living) and III
(motor examination) were evaluated for the study.
Data analysis
Paired t-tests were performed and analyses of variance
using assessment time as repeated measure to compare
the time points. Due to multiple time points we chose the
significance level at p ≤ 0,01.
To identify patient groups a cluster analysis was per-
formed on the preoperative data. The squared Euclidean
distance was used as a proximity measure. The number of
clusters was determined by ending the hierarchical clus-
tering with Ward's minimum variance method at a sharp
increase in the error sum of squares. This criterion indi-
cates that much of the accuracy of classification would be
lost by further reducing the number of groups. Discrimi-
nant function analysis was performed to reassess the
results of the cluster analysis. Additionally we conducted
discriminant function analyses to predict group member-
ship one year and three years postoperatively.
Furthermore, we calculated the Kruskal-Wallis test to
compare age, education, disease duration and MMSE-
score of the four subtypes. Age differences were calculated
using the Chi-Quadrate test (Pearson). Results are pre-
sented as mean (± SD), otherwise indicated.
We analyzed patient data that have been collected in the
study of Kalteis et al (2006) and additionally collected
data three years postoperatively using the same test bat-
tery [25].
Results
Analysis of the preoperative Data
Baseline data were collected at three times prior to surgery
(eight to six weeks, four weeks and two weeks). Since there
were hardly any differences between the preoperative
assessments we combined the preoperative scores to one
baseline mean score. The only exception found was Anxi-
ety. The subscale Anxiety  (SCL-90-R) increased signifi-
cantly from six to two weeks prior to surgery (means: 0,79
± 0,5, 0,92 ± 0,42, T = -2,934, p = 0,007), close to the sur-
gery date anxiety was significantly higher. This finding is
not surprising as the surgical procedure was performed in
awake patients off medication.
Group classification – cluster analysis
Cluster analysis at baseline
Data of one patient were missed for the POMS and SIP
scales; therefore we performed the analysis with 32
patients. Cluster analysis of all self rating scales at baseline
identified four patient subtypes. Subtypes 1 and 2 had low
well-being and higher distress level, subtypes 3 and 4 had
better well-being and less distress compared to the other
groups. Mean scores are listed in Table 2.
Cluster 1 Very low well-being and moderate sickness impact
One fourth of the patients reported very low well-being (n
= 8). They suffered from clinical relevant depressive symp-
toms, increased state and trait anxiety, high distress, but
moderate sickness impact.BMC Neurology 2008, 8:43 http://www.biomedcentral.com/1471-2377/8/43
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Cluster 2: Low well-being and a high sickness impact
22 percent described low well-being, moderate depressive
symptoms and increased state and trait anxiety (n = 7).
Their distress level was moderate and their sickness
impact on quality of life was high.
Cluster 3: Slight decreased well-being and low sickness impact
31 percent of patients specified their well-being and
depressive symptoms as slightly decreased (n = 10). State
anxiety was increased; distress moderate and sickness
impact low.
Cluster 4: Good well-being, little sickness impact
22 percent of patients estimated their well-being as good
(n = 7). Compared to other subtypes few depressive symp-
toms, low anxiety, distress and sickness impact featured
this cluster.
The four subtypes did not differ in age, education and dis-
ease duration (Table 3). Regarding the cognitive screening
there was a trend toward significance (p = 0,018). Subtype
2 indicated the lowest MMSE score. To confirm the results
of the cluster analysis we additionally performed a discri-
minant function analysis of the baseline data. The four
cluster types again differed significantly from each other
(Wilks' Lambda = 0,000, Chi-square 161,34, p = 0,000,
Table 2: Mean scores of the four patient subtypes in the self-rating scales and tests of equality of group means
Self Rating Scales cluster 1 n = 8 cluster 2 n = 7 cluster 3 n = 10 cluster 4 n = 7 Wilks' Lambda F p
Depression (POMS) 18,29 12,57 9,52 3,62 ,534 8,150 ,000
Fatigue (POMS) 13,88 10,10 8,47 6,71 ,543 7,862 ,001
Vigor (POMS) 7,75 4,86 6,57 11,05 ,695 4,101 ,016
Irritability (POMS) 9,54 5,71 3,42 3,95 ,654 4,935 ,007
Well-Being (VAS) 56,64 56,70 56,90 43,85 ,886 1,202 ,327
Depressive Symptoms (BDI) 20,00 15,95 12,17 7,05 ,442 11,771 ,000
State Anxiety (STAI X1) 51,67 51,24 48,27 39,10 ,592 6,436 ,002
Trait Anxiety (STAI X2) 51,81 47,21 43,10 34,93 ,430 12,356 ,000
Somatization(SCL-90-R) 1,46 1,07 1,06 ,70 ,685 4,296 ,013
Obsessive Compulsive (SCL-90-R) 1,09 ,76 ,69 ,45 ,644 5,163 ,006
Interpersonal Sensitivity (SCL-90-R) 1,23 ,73 ,68 ,44 ,625 5,598 ,004
Depression(SCL-90-R) 1,17 ,80 ,73 ,39 ,543 7,870 ,001
Änxiety (SCL-90-R) 1,41 ,86 ,74 ,43 ,349 17,374 ,000
Hostility (SCL-90-R) ,93 ,25 ,23 ,36 ,333 18,669 ,000
Phobic Anxiety (SCL-90-R) ,82 ,41 ,55 ,17 ,725 3,532 ,027
Paranoid Ideation(SCL-90-R) 1,18 ,37 ,60 ,27 ,334 18,600 ,000
Psychoticism (SCL-90-R) ,67 ,41 ,38 ,15 ,500 9,331 ,000
Sleep and Rest (SIP) 2,50 4,14 1,80 1,14 ,532 8,211 ,000
Emotional Behaviour (SIP) 1,94 2,29 1,55 ,57 ,703 3,935 ,018
Body Care and Movement (SIP) 8,25 12,14 5,90 4,93 ,628 5,531 ,004
Home Management (SIP) 3,75 5,64 3,25 2,71 ,729 3,466 ,029
Mobility (SIP) 1,88 4,29 1,45 1,00 ,590 6,478 ,002
Social Interaction (SIP) 7,81 6,14 4,10 2,50 ,510 8,974 ,000
Ambulation (SIP) 4,38 5,43 2,90 1,79 ,570 7,041 ,001
Alertness Behaviour (SIP) 2,94 3,43 2,25 ,86 ,709 3,822 ,021
Communication (SIP) 2,13 4,79 2,65 ,93 ,410 13,450 ,000
Work (SIP) ,75 ,43 ,95 ,57 ,878 1,301 ,294
Recreation and Pastimes (SIP) 4,88 4,14 3,15 2,71 ,609 5,985 ,003
Eating (SIP) ,44 1,79 ,55 ,00 ,416 13,078 ,000
Table 3: Mean scores ± SD of the four patient subtypes and total (age, education, disease duration, MMSE, and distribution between 
the sexes)
cluster 1 n = 8 cluster 2 n = 7 cluster 3 n = 10 cluster 4 n = 7 total n = 32 p
age 60,50 ± 6,30 64,86 ± 3,13 59,00 ± 8,33 56,43 ± 11,24 60,09 ± 8,00 0,345
education (years) 10,13 ± 1,81 11,00 ± 3,00 11,90 ± 2,85 11,14 ± 3,02 11,09 ± 2,66 0,810
disease duration (years) 10,75 ± 3,20 14,43 ± 2,64 15,50 ± 5,80 13,71 ± 5,65 13,69 ± 4,80 0,152
MMSE 28,25 ± 1,03 26,43 ± 0,98 28,50 ± 1,51 27,86 ± 1,07 27,84 ± 1,39 0,018
sex (male/female) 5/3 3/4 8/2 5/2 21/11 0,446BMC Neurology 2008, 8:43 http://www.biomedcentral.com/1471-2377/8/43
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Table 2). The procedure generated a set of discriminant
functions based on linear combinations of the predictor
variables that provided the best discrimination between
the groups. Fisher's linear discriminant functions were
generated from our sample at baseline for which group
membership was defined by the cluster analysis (Table 4).
Profile classification was accurately (100%) repeated in all
patients which confirmed the results of the cluster analysis
to the highest extent. Based on the high accordance of
both statistical procedures the discriminance functions
can be applied to new cases to predict group membership.
Discriminant function analysis one year after surgery
On the basis of the one-year follow-up assessment discri-
minance analysis again revealed significant results. Twelve
months postoperatively the four profiles still significantly
diverged from each other (Wilks' lambda = 0,000, Chi-
square = 131,3, p = 0,000). The predicted classification
remained completely unchanged in 30 patients (two
patients were lost due to death). Mean scores differed sig-
nificantly from baseline, in fact patients showed improve-
ments in almost all self-rating scales one year after surgery.
Despite of this clear amelioration the four patient sub-
groups still differed significantly. Group 1 (n = 7) and 2 (n
= 6) exhibited an impaired psychosocial profile at base-
line compared to the other groups (cluster 3: n = 10, clus-
ter 4: n = 7). Group 1 and 2 improved their mean scores
but both groups still demonstrated an impaired profile
compared to the others.
Discriminant function analysis three years after surgery
The discriminance analysis of the three-year follow-up
showed the same significant pattern as before. Even three
years after surgery the four profiles remained stable
(Wilks' lambda = 0,000, Chi-square = 114,23, p = 0,000).
Noteworthy, mean values of the clinical self-rating scales
returned back to baseline level but the profile classifica-
tion still distinguished between patient groups. A total of
26 patients (one excluded because of missing baseline
data) was correctly classified to cluster 1 (n = 7), cluster 2
(n = 5), cluster 3 (n = 7) and cluster 4 (n = 7).
Pre- and postoperative changes of mood and psychosocial 
functions
Changes in mood and psychosocial functioning in the
course of time are highlighted in detail as follows. All
means (± SD), test statistics and p-values are represented
in Table 5.
Table 4: Classification function coefficients (baseline data)
Self rating scales (baseline) Cluster types
Cluster 1 Cluster 2 Cluster 3 Cluster 4
Depression/Anxiety (POMS) -45,095 1,941 -32,259 -3,105
Fatigue (POMS) -24,082 -40,019 -24,377 -25,016
Vigor (POMS) -51,583 18,876 -31,280 18,696
Irritability (POMS) 75,835 -16,965 48,828 -11,831
Well-Being (VAS) 5,416 4,916 4,372 3,920
Depressive Symptoms (BDI) 3,203 -2,120 3,199 ,444
State anxiety (STAI X1) 38,949 6,157 26,704 4,091
Trait anxiety (STAI X2) -8,686 27,570 ,544 21,373
Somatization (SCL-90-R) 211,872 52,274 172,128 51,987
Obsessive-Compulsive (SCL-90-R) -1532,190 179,417 -979,230 115,394
Interpersonal Sensitivity (SCL-90-R) 41,463 512,705 133,831 382,201
Depression (SCL-90-R) 706,715 311,415 504,843 219,817
Anxiety (SCL-90-R) -391,305 -455,959 -358,736 -359,636
Hostility (SCL-90-R) 485,733 736,884 416,970 486,936
Phobic anxiety (SCL-90-R) 249,424 -218,629 144,239 -138,369
Paranoid Ideation (SCL-90-R) 794,922 -159,428 462,165 -115,188
Psychoticism (SCL-90-R) -521,850 -533,566 -391,216 -344,598
Sleep and Rest (SIP) -105,772 -55,158 -84,909 -39,302
Emotional behaviour (SIP) 272,187 -57,987 166,883 -46,413
Body care (SIP) 114,992 10,448 75,009 8,841
Home management (SIP) -23,264 -9,388 -12,351 -2,577
mobility (SIP) -85,940 19,528 -54,831 7,265
Social interaction (SIP) -94,910 -52,224 -76,480 -36,221
ambulation (SIP) -164,687 123,582 -82,296 85,930
Intellectual capacity (SIP) 135,505 -32,992 87,722 -26,262
communication (SIP) -13,535 130,803 12,335 79,070
Work (SIP) 37,462 -71,851 29,421 -63,390
Recreation and pastimes (SIP) 321,680 31,820 221,404 29,793
(Constant) -1389,236 -1241,196 -942,598 -725,862BMC Neurology 2008, 8:43 http://www.biomedcentral.com/1471-2377/8/43
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POMS
The scores of three subscales (Depression, Fatigue, Vigor) of
this self-rating scale transiently declined in the time
course. However, there was just a trend towards signifi-
cance (p = 0,014, p = 0,013, p = 0,016). The fourth sub-
scale  Irritability  remained unchanged between time
points.
Well-Being (VAS)
The estimation of well-being differed significantly (p =
0,007) in the course of time. The scores of well-being
increased after the surgery up to six months, then slightly
decreased but still differed from baseline. At 36 months
well-being declined again and returned to baseline level.
BDI
Depressive symptoms diminished significantly after sur-
gery and remained stable up to one year (p < 0,001). In
the three-year follow-up the extent of depressive symp-
toms increased and returned to baseline level.
STAI
State and trait anxiety displayed significant changes (both:
p < 0,001). The degree of anxiety decreased after surgery
and lasted up to one year. At three years after surgery it
returned to baseline level.
SCL-90-R
The extent of somatic symptoms (Somatization) declined
significantly and remained stable up to one year (p <
0,001). Afterwards it increased but still significantly dif-
fered from baseline.
Obsessive-compulsive symptoms declined after surgery (p =
0,008). This amelioration persisted up to one year. Three
Table 5: Mean values ± standard deviation at baseline, 3, 6, 12, 36 months postoperatively
Self Rating 
Scales
Baseline (n = 33) 3 months 
(n = 33)
6 months 
(n = 32)
12 months 
(n = 31)
36 months 
(n = 27)
Fp
Depression 
(POMS)
11,09 ± 7,65 7,33 ± 7,65 7,97 ± 8,07 8,61 ± 9,22 11,85 ± 7,13 3,63 0,014
Fatigue (POMS) 9,79 ± 3,92 7,55 ± 4,99 7,84 ± 5,16 7,29 ± 5,18 9,70 ± 4,32 3,44 0,013
Vigor (POMS) 7,47 ± 3,93 8,48 ± 5,34 9,66 ± 4,92 9,29 ± 5,43 6,67 ± 4,52 3,41 0,016
Irritability (POMS) 5,57 ± 4,22 4,33 ± 4,90 4,84 ± 5,60 4,52 ± 4,75 5,33 ± 4,22 1,01 0,398
Well-Being (VAS) 53,85 ± 15,81 38,56 ± 23,96 35,44 ± 16,93 40,77 ± 20,83 48,00 ± 22,91 4,62 0,007
Depressive 
Symptoms (BDI)
13,84 ± 6,20 7,45 ± 6,36 8,47 ± 6,62 7,94 ± 5,56 13,74 ± 5,93 14,70 <0,001
State Anxiety 
(STAI X1)
47,40 ± 7,78 39,12 ± 9,50 40,44 ± 10,32 40,10 ± 9,57 45,74 ± 9,93 9,18 <0,001
Trait Anxiety 
(STAI X2)
44,26 ± 7,94 39,12 ± 10,68 38,44 ± 9,66 39,39 ± 9,40 46,26 ± 8,86 9,28 <0,001
Somatization
(SCL-90-R)
1,06 ± 0,49 0,63 ± 0,38 0,62 ± 0,36 0,62 ± 0,43 0,82 ± 0,45 14,04 <0,001
Obsessive 
Compulsive 
(SCL-90-R)
0,75 ± 0,38 0,51 ± 0,39 0,56 ± 0,46 0,52 ± 0,43 0,67 ± 0,44 4,08 0,008
Interpersonal 
Sensitivity 
(SCL-90-R)
0,77 ± 0,46 0,50 ± 0,42 0,52 ± 0,45 0,39 ± 0,40 0,67 ± 0,47 11,32 <0,001
Depression
(SCL-90-R)
0,79 ± 0,40 0,56 ± 0,46 0,52 ± 0,49 0,53 ± 0,48 0,87 ± 0,52 7,66 <0,001
Änxiety (SCL-90-R) 0,87 ± 0,43 0,32 ± 0,37 0,40 ± 0,43 0,39 ± 0,47 0,50 ± 0,48 14,40 <0,001
Hostility 
(SCL-90-R)
0,43 ± 0,35 0,28 ± 0,25 0,28 ± 0,38 0,25 ± 0,28 0,33 ± 0,38 3,14 0,032
Phobic Anxiety 
(SCL-90-R)
0,50 ± 0,43 0,36 ± 0,38 0,32 ± 0,41 0,36 ± 0,56 0,57 ± 0,65 2,93 0,050
Paranoid 
Ideation(SCL-90-R)
0,62 ± 0,42 0,45 ± 0,43 0,38 ± 0,41 0,37 ± 0,43 0,44 ± 0,49 2,51 0,052
Psychoticism 
(SCL-90-R)
0,41 ± 0,25 0,23 ± 0,27 0,22 ± 0,27 0,25 ± 0,37 0,36 ± 0,33 5,40 0,001
GSI (SCL-90-R) 0,72 ± 0,32 0,44 ± 0,30 0,47 ± 0,34 0,44 ± 0,37 0,61 ± 0,36 10,14 <0,001
PSDI (SCL-90-R) 1,51 ± 0,32 1,34 ± 0,30 1,31 ± 0,26 1,28 ± 0,36 1,43 ± 0,38 3,14 0,027
Physical Domain 
(SIP)
13,30 ± 7,59 6,06 ± 6,90 5,59 ± 6,89 6,16 ± 6,75 11,50 ± 10,42 14,46 <0,001
Psychosocial 
Domain (SIP)
11,70 ± 5,59 7,21 ± 7,17 6,19 ± 6,25 7,29 ± 8,32 13,36 ± 9,34 17,97 <0,001BMC Neurology 2008, 8:43 http://www.biomedcentral.com/1471-2377/8/43
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years after surgery the symptoms increased and returned
to baseline level.
Interpersonal Sensitivity improved after surgery up to one
year. In the three-year follow-up it did not differ signifi-
cantly from baseline (p < 0,001).
This development also applied to the subscale Depression
(p < 0,001).
Anxiety (p < 0,001) significantly improved three months
after surgery. One year postoperatively the score slightly
augmented and further increased in the three-year follow-
up but still was significantly lower compared to baseline
level (p = 0,002). Prior to surgery Anxiety was the only var-
iable that exhibited a marked increase due to the impend-
ing surgery.
Psychotic symptoms declined postoperatively up to 6
months. One year after surgery they slightly worsened but
still differed from baseline (p = 0,001). Three years post-
operatively psychotic symptoms returned to baseline level
again.
The subscales Hostility, Phobic Anxiety, Paranoid Ideation
and Positive Symptom Distress Index exhibited no signifi-
cant changes between the assessments. The Global Severity
Index  significantly changed in the course of time (p <
0,001). After surgery the index score declined and
remained stable up to one year, thereafter it increased and
returned to baseline level.
SIP
Significant changes were also found in the psychosocial (p
< 0,001) and physical domain (p < 0,001) in the course of
time. Both scores improved immediately after surgery at
three months and persisted up to one year. Three years
postoperatively the amelioration was absent as the scores
declined to baseline level.
UPDRS
STN DBS led to a significant improvement in activities of
daily living (part II). Prior to surgery patients were
assessed during the off as well as during the on state. Com-
pared to the off state (baseline med off: 21,5 ± 6,9) there
was a significant and outlasting improvement in the on
state with stimulators turned on (one year: med on/stim
on = 7,3 ± 3,8; three years: med on/stim on = 9,1 ± 5,7,
both p = < 0,000). However, there was no significant dif-
ference between the preoperative on state (med on: 12,0 ±
5,9, p = 0,014) and postoperative scores.
STN DBS induced a clear long-term motor improvement
(part III) compared to both the off and on state at baseline
(baseline med off = 45,2 ± 14,0; baseline med on = 18,0 ±
9,3; 12 months: med on/stim on = 7,2 ± 7,7; 36 months:
12,0 ± 8,3, both p = < 0,001).
Discussion
The present results suggest that prior to surgery patients
with Parkinson's disease can be assigned to four distinct
psychosocial profiles. Even three years after STN DBS this
patient classification remained unchanged. Up to one year
postoperatively there was transient improvement in
mood which had no influence on group membership. The
improvement disappeared in the three-year follow-up as
scores returned back to baseline level. In conclusion, STN
DBS only transiently improved mood and psychosocial
functioning at one year. In the three-year follow-up this
positive effect disappeared and returned to baseline. Thus,
in the long run there was no deterioration in mood and
psychosocial functioning compared to the preoperative
state.
A cluster analysis revealed different psychosocial profiles
that varied in well-being, depressive and anxious symp-
toms, distress and sickness impact. Two clusters were char-
acterized by low well-being and moderate to high sickness
impact. By comparison, the other groups were less
impaired in psychosocial functioning.
Three, six and twelve months after surgery all patients
improved their psychosocial characteristics but patients of
cluster one and two still showed disadvantageous profiles.
Three years postoperatively these ameliorations were
absent but the profiles of all clusters remained relatively
unchanged compared to baseline level.
Based on the patient classification of the cluster analysis it
may possible to individually adjust psychosocial support
to patients' needs. We assume that patients appending to
cluster one or two might need more psychological sup-
port, patients of cluster three and four need less. The
required amount of psychological support could be deter-
mined even prior to surgery as the psychosocial profiles
remained unchanged in the course of time.
Up to one year after surgery comparisons of group means
before and after surgery showed marked improvements in
the majority of psychosocial variables. Well-being signifi-
cantly increased, depressive and anxious symptoms, sick-
ness impact as well as the distress level declined. These
results are consistent with the findings of other groups
[8,9]. Scores of three subscales (depression, fatigue and
vigor) of the POMS were diminished at three, six and
twelve months but these results only showed a trend
towards significance. At the three-year follow-up they
returned to baseline level. The bottom line is no impair-
ment in mood and psychosocial functioning evolved in
the long-term follow-up. Concordantly, no significantBMC Neurology 2008, 8:43 http://www.biomedcentral.com/1471-2377/8/43
Page 8 of 10
(page number not for citation purposes)
changes in depressive or anxiety symptoms have been
reported in other studies [35,36]. Previous studies even
reported worsening of depressive symptoms in a sub-
group of patients [11,13]. In a recent review the overall
finding was that in larger subgroups STN DBS rather had
an antidepressant than depressant effect [37].
So far there are only few long-term studies with respect to
mood alterations after STN DBS. One study revealed a
reduction of depressive symptoms but increased apathy
and thought disorders in the three-year follow-up [8]. In
agreement with our results other authors found less
(although not significantly) depressive symptoms one
year after surgery [5]. Three and even five years after elec-
trode implantation there was no difference to baseline
level.
In line with previous studies the improvement of motor
function declined to small extent but remained stable dur-
ing the entire observation period [5,6,38].
In a previous study depressive symptoms were signifi-
cantly improved three months after surgery, but the extent
of depressive symptoms increased at twelve months and
did not differ from baseline level [7]. Compared to base-
line another group found no changes after STN DBS in
depressive symptoms (six, 24 months and five years post-
operatively) [38]. Accordingly in our study beneficial
effects on well-being, depressive symptoms, state and trait
anxiety, as well as on sickness impact found up to one year
after STN DBS disappeared three years postoperatively.
These results suggest that motor outcome is not related to
psychosocial functioning. One might ask why mood and
well-being of patients declined to the initial point even
though motor symptoms remained improved three years
after surgery. One possible explanation of that effect stems
from economic psychology. According to the prospect
theory values and preferences are not entirely stable [39].
A recently gained profit or advantage soon becomes a mat-
ter of course. Based on that new status quo, losses are
experienced more powerful even though they are smaller
than the antecedent gains. This might be equally valid for
the current results. Although ADL and motor function
slightly declined in the long-term follow-up there still was
a significant improvement compared to baseline. The bot-
tom line was a net profit which may not have been per-
ceived by patients as they only recognized the
proportionally small loss. However, in conclusion STN
DBS had beneficial effects on motor function and activi-
ties of daily living up to three years after surgery.
In summary, STN DBS did not induce deterioration of
mood and psychosocial functions in our patients. The
results showed beneficial short-term effects on mood and
psychosocial functions after one year. In the three-year
follow-up these beneficial effects were absent and scores
returned to the preoperative level. Only amelioration of
somatic symptoms and anxiety measured by the Symp-
tom-Checklist-90-R persisted up to three years which may
be related to the overall decline of motor symptoms. In
this regard it is of note that a previous study reported of a
gain of quality of life in parkinsonian patients twelve
months after electrode implantation which however was
restricted to physical aspects [40]. Mental and social qual-
ity of life did not change in the course of time. Although
they used PD specific scales their findings are in line with
the current results.
Based on our data we found that patients can be assigned
to distinct psychosocial profiles prior to surgery. Since
patient classification did not change in the course of time
the individual amount of psychosocial support can even-
tually be anticipated before surgery in order to prevent or
early detect behavioural abnormalities after STN DBS. In
this regard, further studies should determine how person-
ality traits influence subjective well-being.
Before surgery patients of cluster 1 displayed clinical rele-
vant depression and patients of cluster 2 and 3 were mod-
erately depressed. Their depressive pathology ameliorated
up to one year and long-term results revealed at least no
worsening.
Inclusion criteria of the CAPSIT-PD panel recommend
surgery only for patients free of behavioural abnormalities
because mainly in single case studies deterioration has
been observed after surgery [26]. Besides, behavioural
abnormalities mostly appeared to be transient and results
are too heterogeneous to define universally valid selection
criteria. Following the current inclusion criteria patients
with diagnosed depression are usually meant to be
excluded from STN DBS.
Despite some methodological limitations, especially the
small number of patients, our findings show that STN
DBS is an effective treatment PD patients with mild psy-
chosocial disturbances. Based on the results of the cluster
analysis it is possible to classify patients according to their
psychosocial profile even before surgery. This allows indi-
vidual determination of the extent of the collateral psy-
chological support that is required before surgery and
even in the long run.
Conclusion
Compared to baseline no worsening in mood and psycho-
social functions was found three years after STN DBS.
Moreover, our results suggest that in PD patients with no
to mild psychosocial and psychiatric disturbances, out-
come is not affected by preoperative symptom severity.BMC Neurology 2008, 8:43 http://www.biomedcentral.com/1471-2377/8/43
Page 9 of 10
(page number not for citation purposes)
Patients with mild psychiatric problems need to receive
adequate psychosocial support before and after surgery
instead of being in advance excluded from STN DBS.
Those patients need more attention and psychological
and medical guidance in order to benefit from the motor
improvement. Patients' caregivers and families need to be
aware of the beneficial as well as of the possible negative
effects of STN DBS. In conclusion, our study provides val-
uable suggestions for individual preoperative patient
management and postoperative monitoring.
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